Castle Biosciences Current Ratio 2019-2021 | CSTL

Castle Biosciences current ratio from 2019 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Castle Biosciences Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.39B $0.02B 21.00
2021-03-31 $0.43B $0.02B 24.27
2020-12-31 $0.43B $0.02B 20.58
2020-09-30 $0.20B $0.03B 6.65
2020-06-30 $0.20B $0.03B 6.93
2020-03-31 $0.12B $0.02B 7.64
2019-12-31 $0.12B $0.02B 7.63
2019-09-30 $0.11B $0.01B 11.89
2019-06-30 $0.03B $0.01B 2.43
2019-03-31 $0.00B 0.00
2018-12-31 $0.00B 0.00
2018-09-30 $0.00B 0.00
2018-06-30 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.551B $0.063B
Castle Biosciences Inc. is a commercial-stage dermatological cancer company. It is focused on providing physicians and patients, clinically actionable genomic information. Castle Biosciences Inc. is based in Texas, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86